Crinetics Pharmaceuticals Inc
NASDAQ:CRNX

  • LAST PRICE
    50.8900
  • TODAY'S CHANGE (%)
    3.2300 (6.7772%)
  • Bid / Lots
    50.9000/ 1
  • Ask / Lots
    80.0000/ 5
  • Open / Previous Close
    50.1000 / 47.6600
  • Day Range
    48.4660
    51.2900
  • 52 Week Range
    15.7600
    51.2900
  • Volume
    1,927,255

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
CRNX
Crinetics Pharmaceuticals Inc
3.8B
-13.8x
---
SMMT
Summit Therapeutics Inc
3.7B
-3.2x
---
BHVN
Biohaven Ltd
3.7B
-7.2x
---
IOVA
Iovance Biotherapeutics Inc
3.9B
-7.1x
---
SWTX
SpringWorks Therapeutics Inc
3.4B
-8.2x
---
XENE
Xenon Pharmaceuticals Inc
3.3B
-15.7x
---
As of 2024-05-08

Company Information

Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, oral ACTH antagonist, that is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.

Contact Information

Headquarters
10222 Barnes Canyon Rd Bldg 2SAN DIEGO, CA, United States 92121-2711
Phone
858-450-6464
Fax
302-636-5454

Executives

Independent Chairman of the Board
Wendell Wierenga
President, Chief Executive Officer, Co-Founder, Director
R. Scott Struthers
Co-Founder, Chief Scientific Officer
Stephen Betz
Chief Financial Officer
Marc Wilson
Chief Operating Officer
Jeff Knight

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$3.8B
Revenue (TTM)
$4.0M
Shares Outstanding
78.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.66
EPS
$-3.70
Book Value
$7.91
P/E Ratio
-13.8x
Price/Sales (TTM)
935.2
Price/Cash Flow (TTM)
---
Operating Margin
-5,547.17%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.